top of page

>

>

Portfolio planning and management

Therapeutic Areas

Gene Therapy & Orphan Disease

Client Type

Mid-size Biotech

Client Problems

  • A mid-size biotechnology company wanted to organize its proprietary therapeutic technology portfolio for 3 disease areas


  • They wanted a framework to for portfolio management to drive growth and realize full potential of the platform technology through product and portfolio assessments


  • Specifically, they wanted to identify opportunities, gaps and risks in the portfolio and enable selection and prioritize new programs for internal portfolio

What We Did

  • Initiated a portfolio prioritization methodology and process


  • Established portfolio criteria and metrics based on technical, commercial, operations and strategic fit considerations


  • Rank and prioritize programs in the portfolio alongside external benchmarks


  • Determined the effect of pricing and reimbursement scenarios on the portfolio assets and performed a sensitivity analysis for each scenario

Our Results And Insight

  • Portfolio planning methodology


  • Technical and commercial summary of assets


  • Score based prioritization of portfolio assets


  • Overview of opportunities, gaps and risk analysis


  • Prioritization based on timing, technical and commercial factors


  • Impact of pricing and reimbursement models on portfolio asset sales
case_study_image_placeholder.png
case_study_image_placeholder.png
case_study_image_placeholder.png
case_study_image_placeholder.png
case_study_image_placeholder.png
case_study_image_placeholder.png

See other case studies

Commercial Strategy case studies >

Portfolio Management case studies >

Gene Therapy & Orphan Disease case studies >

Service Areas Details

Commercial Strategy (Indication Prioritization)

Therapeutic Areas Details

Gene Therapy & Orphan Disease

Featured Consultants
bottom of page